ОБЗОРЫ
34
РЕФЛЕКСОТЕРАПИЯ И КОМПЛЕМЕНТАРНАЯ МЕДИЦИНА
№ 1 (7) 2014
27. Pigino G, Morfinia G, Atagia Y, Deshpan-
dec A, Yua C, Jungbauera L, LaDua M, Bus-
ciglioc J, Bradya S. Disruption of fast axonal
transport is a pathogenic mechanism for in-
traneuronal amyloid beta. PNAS: 2009, doi
10.1073/pnas0901229106.
28. Hsieh MT, Peng WH, Wu CR, Wang WH. The
ameliorating effects of the cognitive-enhancing
Chinese herbs on scopolamine-induced amne-
sia in rats. Phytother Res. 2000 Aug;14 (5):375-7.
PubMed PMID: 10925408.
29. Zhang J, Yang JQ, He BC, Zhou QX, Yu HR,
Tang Y, Liu BZ. Berberine and total base from
rhizoma coptis chinensis attenuate brain injury
in an aluminum-induced rat model of neuro-
degenerative disease. Saudi Med J. 2009 Jun;30
(6):760-6. PubMed PMID: 19526156.
30. Shigeta K, Ootaki K, Tatemoto H, Nakanishi T,
Inada A, Muto N. Potentiation of nerve growth
factor-induced neurite outgrowth in PC12 cells
by a Coptidis Rhizoma extract and protoberber-
ine alkaloids. Biosci Biotechnol Biochem. 2002
Nov;66 (11):2491-4. PubMed PMID: 12506995.
31. БилецкийС. В. Эндотелиальнаядисфункция
и патология сердечно-сосудистой системы.
Внутренняя медицина. 2008. №2 (8).
32. Ko WH, Yao XQ, Lau CW, Law WI, Chen ZY,
Kwok W, Ho K, Huang Y. Vasorelaxant and an-
tiproliferative effects of berberine. Eur J Phar-
macol. 2000;399:187-196.
33. Wu M, Wang J, Liu LT. Advance of studies on
anti-atherosclerosis mechanism of berberine.
Chin J Integr Med. 2010 Apr;16 (2):188-92. Re-
view. PubMed PMID: 20473748.
34. Affuso F, Mercurio V, Fazio V, Fazio S. Car-
diovascular and metabolic effects of Berberine.
World J Cardiol. 2010 Apr 26;2 (4):71-7. Pub-
Med PMID: 21160701; PubMed Central PM-
CID: PMC2999047.
35. Hong Y, Hui SC, Chan TY, Hou JY. Effect of
berberine on regression of pressure-overload
induced cardiac hypertrophy in rats. Am J
ChinMed. 2002;30 (4):589-99. PubMed PMID:
12568286.
36. Yin J, Xing H, Ye J. Efficacy of berberine in pa-
tients with type 2 diabetes mellitus. Metabolism.
2008;57:712-17.
37. Zhen Z, Chang B, Li M, Lian FM, Chen L,
Dong L, Wang J, Yu B, Liu WK, Li XY, Qin
PJ, Zhang JH, Tong XL. Anti-diabetic effects
of a Coptis chinensis containing new traditional
Chinese medicine formula in type 2 diabetic
rats. Am J Chin Med. 2011;39 (1):53-63. Pub-
Med PMID: 21213398.
38. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ,
Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, et
al. Berberine, a natural plant product, activates
AMP-activated protein kinase with beneficial
metabolic effects in diabetic and insulin-resist-
ant states. Diabetes. 2006;55:2256-64.
39. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang
Y, Yang D, Liang H, Ye J, Weng J. Berber-
ine improves glucose metabolism in diabetic
rats by inhibition of hepatic gluconeogenesis.
PLoS One. 2011 Feb 3;6 (2):e16556. PubMed
PMID: 21304897; PubMed Central PMCID:
PMC3033390.
40. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N,
Huo L, Wang M, Hong J, Wu P, et al. Treatment
of type 2 diabetes and dyslipidemia with the nat-
ural plant alkaloid berberine. J Clin Endocrinol
Metab. 2008;93:2559-65.
41. Kong WJ, Zhang H, Song DQ, Xue R, Zhao
W, Wei J, Wang YM, Shan N, Zhou ZX, Yang
P, et al. Berberine reduces insulin resistance
through protein kinase C-dependent up-regula-
tion of insulin receptor expression. Metabolism.
2009;58:109-119.
42. Li J, Meng X, Fan X, Lai X, Zhang Y, Zeng Y.
[Pharmacodyamic material basis of rhizoma
coptidis on insulin resistance]. Zhongguo Zhong
Yao Za Zhi. 2010 Jul;35 (14):1855-8. Chinese.
PubMed PMID: 20939284.
43. Yokozawa T, Ishida A, Cho EJ, Nakaga-
wa T. The effects of Coptidis Rhizoma extract
on a hypercholesterolemic animal model. Phy-
tomedicine. 2003 Jan;10 (1):17-22. PubMed
PMID: 12622459.
44. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C,
Wang Y, Wang Z, Si S, Pan H, et al. Berber-
ine is a novel cholesterol-lowering drug work-
ing through a unique mechanism distinct from
statins. Nat Med. 2004;10:1344-51. PubMed
PMID: 15531889.
45. Brusq JM, Ancellin N, Grondin P, Guillard
R, Martin S, Saintillan Y, Issandou M. Inhi-
bition of lipid synthesis through activation of
AMP kinase: an additional mechanism for the
hypolipidemic effects of berberine. J Lipid Res.
2006;47:1281-1288.
46. Tan Y, Kamal MA, Wang ZZ, Xiao W, Seale JP,
Qu X. Chinese herbal extracts (SK0506) as a
potential candidate for the therapy of the meta-
bolic syndrome. Clin Sci (Lond). 2011 Apr;120
(7):297-305. PubMed PMID: 20950275.
47. Cicero AF, Rovati LC, Setnikar I. Eulipidemic
effects of berberine administered alone or in
combination with other natural cholesterol-low-
ering agents. A single-blind clinical investiga-
tion. Arzneimittelforschung. 2007;57:26-30.
48. Государственный реестр лекарственных
средств. Официальное издание (по сост. на 1
апреля 2008 г.). М., 2008. Т. I. 1398 с.